Logo image of ENTX

ENTERA BIO LTD (ENTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ENTX - IL0011429839 - Common Stock

1.78 USD
+0.02 (+1.14%)
Last: 12/24/2025, 9:30:00 AM
Fundamental Rating

3

Overall ENTX gets a fundamental rating of 3 out of 10. We evaluated ENTX against 530 industry peers in the Biotechnology industry. ENTX has a great financial health rating, but its profitability evaluates not so good. ENTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENTX had negative earnings in the past year.
ENTX had a negative operating cash flow in the past year.
In the past 5 years ENTX always reported negative net income.
ENTX had a negative operating cash flow in each of the past 5 years.
ENTX Yearly Net Income VS EBIT VS OCF VS FCFENTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

ENTX has a Return On Assets (-61.93%) which is in line with its industry peers.
With a Return On Equity value of -70.77%, ENTX perfoms like the industry average, outperforming 55.66% of the companies in the same industry.
Industry RankSector Rank
ROA -61.93%
ROE -70.77%
ROIC N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ENTX Yearly ROA, ROE, ROICENTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

ENTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTX Yearly Profit, Operating, Gross MarginsENTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ENTX has more shares outstanding
ENTX has more shares outstanding than it did 5 years ago.
ENTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTX Yearly Shares OutstandingENTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ENTX Yearly Total Debt VS Total AssetsENTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 11.47 indicates that ENTX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 11.47, ENTX belongs to the best of the industry, outperforming 83.40% of the companies in the same industry.
There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.47
ROIC/WACCN/A
WACC8.6%
ENTX Yearly LT Debt VS Equity VS FCFENTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

ENTX has a Current Ratio of 10.83. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.83, ENTX belongs to the best of the industry, outperforming 85.09% of the companies in the same industry.
ENTX has a Quick Ratio of 10.83. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.83, ENTX belongs to the best of the industry, outperforming 85.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.83
Quick Ratio 10.83
ENTX Yearly Current Assets VS Current LiabilitesENTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

ENTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
Measured over the past years, ENTX shows a decrease in Revenue. The Revenue has been decreasing by -5.49% on average per year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, ENTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -65.34% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-30.56%
EPS Next 2Y-65.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-69.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTX Yearly Revenue VS EstimatesENTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2025 0 200K 400K
ENTX Yearly EPS VS EstimatesENTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTX Price Earnings VS Forward Price EarningsENTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTX Per share dataENTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as ENTX's earnings are expected to decrease with -65.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-65.34%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ENTERA BIO LTD

NASDAQ:ENTX (12/24/2025, 9:30:00 AM)

1.78

+0.02 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-26 2026-03-26/amc
Inst Owners19.74%
Inst Owner Change-10.05%
Ins Owners2.41%
Ins Owner Change2.77%
Market Cap81.63M
Revenue(TTM)124.00K
Net Income(TTM)-10.78M
Analysts82.86
Price TargetN/A
Short Float %0.3%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.14%
Min EPS beat(2)23.75%
Max EPS beat(2)46.52%
EPS beat(4)4
Avg EPS beat(4)70.19%
Min EPS beat(4)23.75%
Max EPS beat(4)184.03%
EPS beat(8)7
Avg EPS beat(8)32.3%
EPS beat(12)10
Avg EPS beat(12)25.72%
EPS beat(16)14
Avg EPS beat(16)25.06%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)41.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 658.31
P/FCF N/A
P/OCF N/A
P/B 5.36
P/tB 5.36
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.93%
ROE -70.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 244.12%
Cap/Sales 66.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.83
Quick Ratio 10.83
Altman-Z 11.47
F-Score5
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)40.07%
Cap/Depr(5y)48.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-30.56%
EPS Next 2Y-65.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%-100%
Revenue Next Year-69.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.54%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERA BIO LTD / ENTX FAQ

What is the fundamental rating for ENTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to ENTX.


What is the valuation status for ENTX stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTERA BIO LTD (ENTX). This can be considered as Overvalued.


How profitable is ENTERA BIO LTD (ENTX) stock?

ENTERA BIO LTD (ENTX) has a profitability rating of 1 / 10.